Advertisement

Topics

BioLight Life Sciences (BOLT) - IOPtiMate sales slow as Asian distribution on hold

07:06 EDT 12 Sep 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - BioLight Life Sciences: BioLight reported H117 results in late August and IOPtiMate revenue was lower than expected, due to a pause in distributor activity in China. This interruption may last until there is a definitive conclusion in the pending Chengdu transaction. We have decreased our near-term IOPtiMate forecasts and extended the time runway estimated to achieve our peak sales targets for the product. We now derive an rNPV of NIS109.7-130.7m (down from NIS121.6-135.7m, previously).
ISIN: IL0010952237

Original Article: BioLight Life Sciences (BOLT) - IOPtiMate sales slow as Asian distribution on hold

NEXT ARTICLE

More From BioPortfolio on "BioLight Life Sciences (BOLT) - IOPtiMate sales slow as Asian distribution on hold"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...